Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technology to empower cancer care, today announced it has opened its U.S. operations center in Aurora, Colorado. This opening is in support of the company’s recent launch of the StrandAdvantage pan-cancer genomic profiling service.
Available now to physicians, StrandAdvantage was designed to accelerate the analysis of therapeutically actionable cancer genes and match them to relevant FDA-approved targeted cancer therapies and open clinical trials without the need for multiple tests.